Focused ultrasound to enhance chemotherapy for brainstem glioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether using focused ultrasound to temporarily open the blood-brain barrier can help chemotherapy (temozolomide) reach a brain tumor called diffuse midline glioma more effectively. The goal is to see if this procedure is safe and feasible in patients who have already completed radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 4 years old.
- You must have a confirmed diagnosis of diffuse midline glioma with a specific genetic change (H3K27-altered) in the brainstem.
- You must be in generally good health, with a performance status of 70% or higher (meaning you can do most daily activities).
- You must have completed radiation therapy and be planning to continue with chemotherapy (temozolomide).
- You cannot have other serious medical conditions like bleeding disorders, severe heart, kidney, or liver problems.
- You must be willing and able to attend all study visits and give consent (or have a guardian do so).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
This study looks at using focused ultrasound to temporarily loosen the brain’s “blood barrier” around certain brain tumors, while people still get standard surgery. It aims to help doctors learn how safe the approach is and collect blood/fluid samples during the operation.
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
This early-phase study tests whether focusing ultrasound (FUS) plus etoposide can help treat children and teens with diffuse midline glioma that affects the brainstem (pons) and/or thalamus, especially with an H3K27M change. Participants must have cancer that is getting worse and be healthy enough to safely receive study treatment.
This trial tests a new way to treat a type of brain tumor called diffuse midline glioma. It uses focused ultrasound to open a tiny gap in the blood-brain barrier, which may help special immune cells (T-cells) reach and attack the tumor. The goal is to see if this combination is safe and helpful.
Hear when a new Diffuse Midline Glioma, H3 K27-Altered trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.